107. MPTP-lesioned monkeys were gavaged with L-dopa/carbidopa (10 and 2.5 mg/kg, respectively) twice daily, which resulted in stable LIDs. A dose response study (0.03-1.0 mg/kg) showed that oral ABT-107 decreased LIDs by 40-60%. LIDs returned to control levels only after a 6-wk ABT-107 washout, suggesting long term molecular changes were involved. Subsequent re-administration of ABT-107 decreased LIDs by 50-60%, indicating tolerance did not develop.
There was no effect of ABT-107 on parkinsonism or cognitive performance. We next tested ABT-107 together with the β 2 agonist ABT-894, previously shown to reduce LIDs in parkinsonian monkeys. In one study, the monkeys were first given oral ABT-894 (0.01 mg/kg), which maximally decreased LIDs by 50-60%; they were then also treated with 0.1 mg/kg ABT-107, a dose that maximally reduced LIDs. The effect of combined treatment on LIDs was similar to that with either drug alone. Comparable results were observed in a group of monkeys first treated with ABT-107 and then also given ABT-894. Thus, α 7 and β 2 nAChR selective drugs may function via a final common mechanism to reduce LIDs. The present results suggest that drugs targeting either α 7 or β 2 nAChRs may be useful as antidyskinetic agents in Parkinson's disease.
Introduction
A critical unmet need for Parkinson's disease management is a strategy to reduce L-dopa-induced dyskinesias (LIDs). These abnormal involuntary movements are a serious debilitating side effect of L-dopa therapy, the gold-standard treatment for Parkinson's disease, and develop in most patients with continued L-dopa use (Obeso et al., 2010; Meissner et al., 2011; Schapira and Jenner, 2011; Wichmann et al., 2011; Iravani et al., 2012; Huot et al., 2013) . Currently the only drug approved for LIDs is amantadine, and it is of only limited effectiveness. There is therefore an ongoing search for new therapies. Drugs targeting numerous classes of neurotransmitter receptors, including glutamatergic, serotonergic, cholinergic and others, reduce LIDs in animal models, suggesting that multiple mechanisms are involved (Fox et al., 2009; Brotchie and Jenner, 2011; Blandini and Armentero, 2012; Duty, 2012; Sgambato-Faure and Cenci, 2012; Huot et al., 2013) .
More recent studies also indicate the nicotinic cholinergic system is involved in LIDs.
Studies in mice, rats and monkeys showed that the general nAChR agonist nicotine consistently reduced LIDs in a dose dependent manner (Quik et al., 2007; Bordia et al., 2008; Huang et al., 2011a; Quik et al., 2013d) . Tolerance did not arise to the antidyskinetic effect of nicotine, even with months of treatment. Moreover, nicotine reduced LIDs whether administered prior to Ldopa treatment or once LIDs developed.
Nicotine generally exerts its effect by acting at nAChRs of which there are multiple subtypes in both the peripheral and central nervous system. These include the α 1β1*, α 3β4* and α 7 nAChRs in the periphery, with the α 4β2*, α 6β2* and α 7 nAChRs being the primary ones in the brain (Millar and Gotti, 2009; Quik and Wonnacott, 2011 
Induction of LIDs.
The monkeys were injected subcutaneously with 2.0 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; Sigma-Aldrich, St. Louis, MO) dissolved in saline to render them parkinsonian (Quik et al., 2007) . After a 3-4 wk recovery period from the systemic effects of MPTP injection, the monkeys were rated for parkinsonism. Parkinsonism was assessed by evaluating spatial hypokinesia, body bradykinesia, left and right manual dexterity, balance at rest and during movement, freezing during movement and action tremor, with each category rated from 0 (normal) to 4 (severely parkinsonian), as described (Quik et al., 2007; Quik et al., 2013d) . The maximum parkinsonian score is 28; however, individual scores are considerably less because parkinsonism is variably expressed in the monkeys. Any one monkey may have deficits in manual dexterity, but exhibit no freezing or tremor and move well, while another monkey may exhibit freezing and tremor but have no motor deficits. If the monkeys were not parkinsonian, MPTP injection was repeated at 1.9 mg/kg. Parkinsonism was rated once weekly on Fridays throughout the study, before and 90 min after L-dopa administration.
Monkeys were then gavaged with L-dopa (10 mg/kg) and carbidopa (2.5 mg/kg) twice a day Dyskinesias were assessed on a scale of 0 (no dyskinesias) to 4 (severe dyskinesias) using the following criteria: 1 = subtle dyskinesias that were not sustained (< 3 trunk movements in a row); 2 = sustained dyskinesias (≥ 3 trunk movements in a row); 3 = moderate dyskinesias that impaired the ability to remain stationary; and 4 = severe dyskinesias that were generalized and incapacitating (Tan et al., 2002; Quik et al., 2007; Quik et al., 2013d) .
nAChR drug treatments. The monkeys had previously been treated with other nAChR agonists, followed by a 1 month washout period before initiating the current study. LID scores were at vehicle-treated levels for all monkeys groups at the start of the drug treatment regimens.
The groups were as follows: a vehicle-treated group (n = 6), a nicotine-treated (n = 5) group, a group of monkeys first treated with ABT-107 and subsequently also given ABT-894 (n = 5), and a group first treated with ABT-894 and then also administered ABT-107 (n = 5). There were similar number of males and females in each group.
All monkeys received 50% diluted orange Gatorade in the drinking water as a vehicle control for nicotine treatment. The presence of the Gatorade was necessary to mask the bitter taste of nicotine ((-)-nicotine, free base; Sigma-Aldrich, St. Louis, MO) in the nicotine-treated group.
The dose of nicotine was started at 50 μg/ml for 2-3 days, increased to 150 µg/ml for a further 3-4 days and then to 300 μg/ml nicotine at which it was maintained for the remainder of the study, This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on July 17, 2014 as DOI: 10.1124 at ASPET Journals on July 8, 2017
jpet.aspetjournals.org Downloaded from
as described (Quik et al., 2006; Quik et al., 2013d; Zhang et al., 2013a) . Gatorade with and without nicotine was also added to the dry monkey chow. This nicotine dosing regimen yielded monkey plasma nicotine and cotinine levels similar to those in moderate smokers (Quik et al., 2006; Matta et al., 2007) . ABT-107 or ABT-894 was administered orally 5 days per week via a small cracker 30 min before L-dopa gavage. Each drug was applied to a small cracker in a 30-40 µl aliquot of water (depending on monkey weight) and immediately given to the monkeys. The drug had no effect on body weight; no adverse effects were noted on behavior.
Cognitive testing. Since nAChR drugs are known to modulate cognitive abilities, we evaluated the effect of ABT-107 on cognition. We used an object retrieval task previously used for squirrel monkeys that measures a component of prefrontal cortex-dependent cognitive control involving inhibition of an initial learned response after subsequent spatial reversals (Lyons et al., 2000; Lyons et al., 2004; Zhang et al., 2013a) . The monkeys were scored for the average time and number of trials required to retrieve the marshmallow piece within a 30 sec period (Lyons et al., 2000; Lyons and Schatzberg, 2003 Fig. 1 top panel) . ABT-107 (0.03 to 1.0 mg/kg) was given orally in a cracker 30 min prior to L-dopa. The results ( Fig. 1 middle panel) show that ABT-107 significantly reduced LIDs by 40% at the 0.03 mg/kg dose, and maximally by 50% at the 0.10 mg/dose. The effect of nicotine on LIDs is shown for comparison ( Fig. 1 bottom panel) .
Nicotine significantly reduced LIDs by 50-70%. Both ABT-107 and nicotine treatment reduced LIDs throughout the 4 h time course compared to vehicle, with the median scores shown (Fig. 2) .
The dyskinesia scores in the vehicle-treated monkeys ( Fig. 2) ranged from 1.0-2.0; thus the monkeys were moderately dyskinetic. The dyskinesia scores decreased to 0-1.0 with drug treatment (Fig. 2) . After the 4 week drug treatment regimen, ABT-107 and nicotine were discontinued. The results in Fig. 3 show that LIDs only returned to vehicle-treated levels by 6 wk of either ABT-107 or nicotine washout.
Combined effect of the α 7 agonist ABT-107 and the β 2* nAChR agonist ABT-894 on LIDs. Our previous studies had shown that the β 2 nAChR agonist ABT-894 reduced LIDs by 60% similar to the current results with α 7 agonist ABT-107 (Zhang et al., 2014) . This raised the question whether combined treatment with the two different classes of nAChR agonists may yield a greater decline in LIDs than either drug alone. To evaluate this possibility monkeys were treated with both drugs in combination as follows. One set of monkeys (n = 5) was first treated with 0.10 mg/kg ABT-107, a dose that maximally decreases LIDs (Fig. 4A) . The monkeys were given ABT-107 orally for 5 wk to ensure the drug effect had plateaud. A 50-60% decline in LIDs was obtained throughout the entire period. At week 6, the monkeys were also orally given ABT-894 at a dose that optimally reduced LIDs (0.01 mg/kg) (Zhang et al., 2014 with combined ABT-107 plus ABT-894 treatment was similar to that observed with ABT-107 alone (Fig. 4A ).
Another set of monkeys ( (Table 1 ). The scores shown are for the last 4 wk of treatment, with similar results throughout the study. In addition, ABT-107 had no effect on cognitive performance at any dose tested (Table 2 ).
This article has not been copyedited and formatted. The final version may differ from this version. whereas ABT-894 reduced LIDs up to 60% in nonhuman primates (Zhang et al., 2014) . None of the agonists worsened parkinsonism, and there were no detectable side effects and no emesis (Zhang et al., 2014) . Moreover, the effects of both the β 2* nAChR drug ABT-894, the α 7 nAChR drug ABT-107, as well as nicotine, persisted for months with treatment and, in addition, remained for several weeks after drug continuation.
α 7 nAChRs are functionally and pharmacologically distinct from β 2* nAChRs. They exhibit a greater calcium conductance and faster desensitization, and have a more direct impact on glutamatergic signaling (Albuquerque et al., 2009; Quik and Wonnacott, 2011) . These differential characteristics raised the question whether combination α 7 and β 2* nAChR drug treatment may yield a greater decline in LIDs. However, when ABT-107 was tested together with the β2* nAChR agonist ABT-894, the improvement in LIDs was comparable to that with either drug alone. In addition, it was similar to the effect of nicotine, a general agonist that acts at both α7 and β2* nAChRs, although with lower affinity for the α 7 subtype.
The finding that the β 2* and α 7 nAChR agonists both reduce LIDs by ~60% but show no significant additive effect with combined treatments suggests that these classes of drugs either reduce LIDs by a common mechanism or decrease LIDs by affecting different mechanism(s), which ultimately converge to produce parallel downstream changes. A key brain region involved in the generation of LIDs is the striatum, which expresses both β 2 and α 7 nAChRs. Although not at high density (Quik et al., 2000) , α 7 nAChRs are located on glutamatergic afferents from the cortex to the striatum to regulate dopamine release (Kaiser and Wonnacott, 2000) . In addition, α 7 nAChRs are present in the substantia nigra to control striatal dopaminergic function (Quik et al., 2000) . β 2* nAChR receptors are also expressed in the striatum on striatal dopamine nerve terminals as well as other neuronal elements. Lesion studies suggest that the β 2* nAChRs on the dopamine nerve terminals are important for the nAChR -mediated reduction in LIDs because nicotine and nAChR drugs most effectively reduced LIDs in parkinsonian animals with moderate nigrostriatal damage (Huang et al., 2011a; Huang et al., 2011b; Quik et al., 2013c) . Thus, a common mechanisms by which α 7 and β 2* nAChR drugs act to reduce LIDs may involve a reduction in striatal dopamine release. Further evidence for this suggestions stems from studies
showing that long term nicotine treatment reduces dopamine release from striatal synaptosomes (Bordia et al., 2013) .
In addition to the nigrostriatal dopaminergic system, other neuronal pathways also appear to be involved in the nAChR-mediated decline in LIDs. Evidence for this idea stems from studies showing that nicotine and β 2* nAChR drugs still diminished LIDs up to 30% in rats with severe nigrostriatal damage. Possible candidates include nAChRs on nondopaminergic striatal neurons (GABAergic or cholinergic) or nAChRs in other brain regions (Huang et al., 2011b; Quik et al., 2013e) . The effects of α7 nAChR drugs may also be mediated by α 7 nAChRs in cortex, thalamus, cerebellum and other brain regions linked to motor control, since there is relatively high expression of α 7 nAChRs in these regions (Quik et al., 2000) .
With respect to the signaling pathways affected by nAChR drugs, activation of the nicotinic acetylcholine system has been linked to alterations in cAMP-linked intracellular signaling and in extracellular signal-regulated kinases (ERK) (Ding et al., 2011; Feyder et al., 2011; Kawamata This article has not been copyedited and formatted. The final version may differ from this version. and Shimohama, 2011). Changes in the cAMP signaling cascade including activation of cAMP, increased activity of the cAMP-dependent protein kinase (PKA) and of the dopamine-and cAMP-dependent phosphoprotein of 32 kDa (DARPP-32) have also been implicated in LIDs (Santini et al., 2007; Calabresi et al., 2008; Rangel-Barajas et al., 2010; Santini et al., 2010; Feyder et al., 2011) . As well, LIDs are associated with enhanced activity of ERK (Santini et al., 2010; Feyder et al., 2011; Wang et al., 2012) . These mechanisms and others may thus contribute to the nAChR-mediated reduction in LIDs.
The ability of ABT-894, ABT-107 and nicotine to reduce LIDs weeks after drug discontinuation suggests that they most likely induce their effect via long-lasting molecular adaptations. Indeed, long-term changes in gene-expression, intracellular signaling pathways, neuronal plasticity and morphology have all been linked to the expression of LIDs (Santini et al., 2009; Cenci and Konradi, 2010; Feyder et al., 2011; Huot et al., 2011; Rangel-Barajas et al., 2011; Zhang et al., 2013b) . Moreover, these changes may occur via numerous neurotransmitter systems such as the dopaminergic, glutamatergic, serotonergic and others, which are all implicated in the development and maintenance of LIDs (Carta and Bezard, 2011; Huot et al., 2011; Blandini and Armentero, 2012; Duty, 2012; Rylander, 2012; Huot et al., 2013) .
α7 nAChR agonists offer the advantage that they have also been linked to improvements in cognition in numerous animal models (Levin, 2012; Lendvai et al., 2013) and in various neurological/psychiatric disorders (Geerts, 2012; Lieberman et al., 2013) . These latter observations suggest that α7 nAChR drugs may also be helpful for the memory deficits with
Parkinson's disease, in addition to improving LIDs.
In summary, the present data show that the α 7 nAChR agonist ABT-107 reduces LIDs in parkinsonian monkeys, without affecting parkinsonism. Our previous work showed similar Significance of difference from vehicle using a Mann-Whitney test, **p < 0.01 ***p < 0.001. ***p < 0.001 using two-way ANOVA followed by a Bonferroni post hoc test. 
